154 related articles for article (PubMed ID: 25804839)
1. Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma.
Herold M; Scholz CW; Rothmann F; Hirt C; Lakner V; Naumann R
J Cancer Res Clin Oncol; 2015 Sep; 141(9):1689-95. PubMed ID: 25804839
[TBL] [Abstract][Full Text] [Related]
2. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
4. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
5. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
[TBL] [Abstract][Full Text] [Related]
6. The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Bishton MJ; Rule S; Wilson W; Turner D; Patmore R; Clifton-Hadley L; McMillan A; Lush R; Haynes A
Br J Haematol; 2020 Aug; 190(4):545-554. PubMed ID: 32150649
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients.
Hirt C; Schüler F; Kiefer T; Schwenke C; Haas A; Niederwieser D; Neser S; Assmann M; Srock S; Rohrberg R; Dachselt K; Leithäuser M; Rabkin CS; Herold M; Dölken G
Br J Haematol; 2008 May; 141(5):631-40. PubMed ID: 18422779
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.
Ray JA; Carr E; Lewis G; Marcus R
Value Health; 2010; 13(4):346-57. PubMed ID: 20070643
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
Južnič Šetina T; Borštnar S; Jezeršek Novaković B
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
[TBL] [Abstract][Full Text] [Related]
10. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.
Barzenje DA; Cvancarova Småstuen M; Liestøl K; Fosså A; Delabie J; Kolstad A; Holte H
PLoS One; 2015; 10(7):e0131158. PubMed ID: 26147646
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Karmali R; Kassar M; Venugopal P; Shammo JM; Fung HC; Bayer R; O'Brien T; Gregory SA
Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):467-74. PubMed ID: 21700527
[TBL] [Abstract][Full Text] [Related]
13. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
14. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
Vitolo U; Ladetto M; Boccomini C; Baldini L; De Angelis F; Tucci A; Botto B; Chiappella A; Chiarenza A; Pinto A; De Renzo A; Zaja F; Castellino C; Bari A; Alvarez De Celis I; Evangelista A; Parvis G; Gamba E; Lobetti-Bodoni C; Ciccone G; Rossi G
J Clin Oncol; 2013 Sep; 31(27):3351-9. PubMed ID: 23960180
[TBL] [Abstract][Full Text] [Related]
15. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
17. Prediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.
Murakami S; Kato H; Higuchi Y; Yamamoto K; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
Ann Hematol; 2016 Aug; 95(8):1259-69. PubMed ID: 27220639
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
19. A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
Bari A; Marcheselli R; Marcheselli L; Alvarez I; Pozzi S; Ferri P; Lazzaro A; Fragasso A; Neri S; Baldini L; Carella AM; Angrilli F; Guariglia R; Buda G; Stelitano C; Sacchi S;
Acta Haematol; 2017; 137(1):7-14. PubMed ID: 27820922
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
